Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 20, 2022
Product Development
Barron’s departure leaves unfinished business in GSK’s cancer pipeline
CSO stepping down to join biopharma ‘dream team’ at newly launched Altos
BioCentury | Dec 17, 2021
Product Development
How digital is evolving at pharmas
The definition of digital is coming into focus at pharmas as data science becomes the central value driver
BioCentury | Jun 14, 2021
Deals
GSK fuels TIGIT frenzy with $625M payout for iTeos’ mAb
iTeos’ Phase I anti-TIGIT mAb draws one of the largest-ever immuno-oncology deals
BioCentury | Dec 18, 2020
Product Development
Next-generation checkpoints acting on NK and T cells: Data Byte
Following the early success of anti-TIGIT mAbs in clinical development this year, interest in next-generation checkpoints has been on the rise, and there’s reason to believe that checkpoints
Items per page:
1 - 4 of 4